XERIS BIOPHARMA HOLDINGS INC (XERS) Fundamental Analysis & Valuation

NASDAQ:XERS • US98422E1038

Current stock price

5.61 USD
+0.12 (+2.19%)
At close:
5.61 USD
0 (0%)
After Hours:

This XERS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. XERS Profitability Analysis

1.1 Basic Checks

  • XERS had negative earnings in the past year.
  • In the past year XERS had a positive cash flow from operations.
  • In the past 5 years XERS reported 4 times negative net income.
  • XERS had negative operating cash flow in 4 of the past 5 years.
XERS Yearly Net Income VS EBIT VS OCF VS FCFXERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • The Return On Assets of XERS (0.14%) is better than 78.65% of its industry peers.
  • With an excellent Return On Equity value of 4.05%, XERS belongs to the best of the industry, outperforming 82.81% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 7.18%, XERS belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
Industry RankSector Rank
ROA 0.14%
ROE 4.05%
ROIC 7.18%
ROA(3y)-12.04%
ROA(5y)-20.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XERS Yearly ROA, ROE, ROICXERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • XERS has a Profit Margin of 0.19%. This is in the better half of the industry: XERS outperforms 78.65% of its industry peers.
  • XERS has a better Operating Margin (8.53%) than 80.73% of its industry peers.
  • XERS's Gross Margin of 85.41% is amongst the best of the industry. XERS outperforms 88.54% of its industry peers.
  • XERS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.53%
PM (TTM) 0.19%
GM 85.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.42%
GM growth 5Y9.44%
XERS Yearly Profit, Operating, Gross MarginsXERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. XERS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XERS is destroying value.
  • Compared to 1 year ago, XERS has more shares outstanding
  • XERS has more shares outstanding than it did 5 years ago.
  • XERS has a better debt/assets ratio than last year.
XERS Yearly Shares OutstandingXERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
XERS Yearly Total Debt VS Total AssetsXERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of 0.41, we must say that XERS is in the distress zone and has some risk of bankruptcy.
  • XERS has a Altman-Z score (0.41) which is in line with its industry peers.
  • The Debt to FCF ratio of XERS is 7.89, which is on the high side as it means it would take XERS, 7.89 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of XERS (7.89) is better than 80.21% of its industry peers.
  • A Debt/Equity ratio of 16.10 is on the high side and indicates that XERS has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 16.10, XERS is doing worse than 82.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 16.1
Debt/FCF 7.89
Altman-Z 0.41
ROIC/WACC0.7
WACC10.19%
XERS Yearly LT Debt VS Equity VS FCFXERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • XERS has a Current Ratio of 2.19. This indicates that XERS is financially healthy and has no problem in meeting its short term obligations.
  • XERS's Current ratio of 2.19 is in line compared to the rest of the industry. XERS outperforms 42.71% of its industry peers.
  • XERS has a Quick Ratio of 1.57. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
  • XERS has a Quick ratio of 1.57. This is comparable to the rest of the industry: XERS outperforms 40.10% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.57
XERS Yearly Current Assets VS Current LiabilitesXERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. XERS Growth Analysis

3.1 Past

  • XERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.37%, which is quite impressive.
  • XERS shows a strong growth in Revenue. In the last year, the Revenue has grown by 43.72%.
  • XERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.26% yearly.
EPS 1Y (TTM)97.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y38.35%
Revenue growth 5Y70.26%
Sales Q2Q%42.78%

3.2 Future

  • The Earnings Per Share is expected to grow by 158.41% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, XERS will show a quite strong growth in Revenue. The Revenue will grow by 19.20% on average per year.
EPS Next Y1951.3%
EPS Next 2Y518.97%
EPS Next 3Y289.56%
EPS Next 5Y158.41%
Revenue Next Year27.72%
Revenue Next 2Y22.93%
Revenue Next 3Y19.87%
Revenue Next 5Y19.2%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XERS Yearly Revenue VS EstimatesXERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
XERS Yearly EPS VS EstimatesXERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

5

4. XERS Valuation Analysis

4.1 Price/Earnings Ratio

  • XERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 30.30, which means the current valuation is very expensive for XERS.
  • Based on the Price/Forward Earnings ratio, XERS is valued a bit cheaper than 72.92% of the companies in the same industry.
  • XERS is valuated rather expensively when we compare the Price/Forward Earnings ratio to 24.12, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 30.3
XERS Price Earnings VS Forward Price EarningsXERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XERS indicates a somewhat cheap valuation: XERS is cheaper than 78.65% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, XERS is valued cheaper than 80.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF 33.33
EV/EBITDA 27.53
XERS Per share dataXERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • XERS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as XERS's earnings are expected to grow with 289.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y518.97%
EPS Next 3Y289.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XERS Dividend Analysis

5.1 Amount

  • No dividends for XERS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XERS Fundamentals: All Metrics, Ratios and Statistics

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (3/17/2026, 8:00:02 PM)

After market: 5.61 0 (0%)

5.61

+0.12 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners61.48%
Inst Owner Change2.03%
Ins Owners2.74%
Ins Owner Change0.64%
Market Cap930.81M
Revenue(TTM)291.85M
Net Income(TTM)554.00K
Analysts84.62
Price Target11.37 (102.67%)
Short Float %10.68%
Short Ratio7.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-33.16%
Min EPS beat(2)-100%
Max EPS beat(2)33.69%
EPS beat(4)2
Avg EPS beat(4)-3.07%
Min EPS beat(4)-100%
Max EPS beat(4)64.35%
EPS beat(8)4
Avg EPS beat(8)1.49%
EPS beat(12)6
Avg EPS beat(12)4.83%
EPS beat(16)10
Avg EPS beat(16)7.7%
Revenue beat(2)1
Avg Revenue beat(2)0.24%
Min Revenue beat(2)-1.7%
Max Revenue beat(2)2.17%
Revenue beat(4)3
Avg Revenue beat(4)2.85%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)8.61%
Revenue beat(8)6
Avg Revenue beat(8)1.8%
Revenue beat(12)9
Avg Revenue beat(12)3.53%
Revenue beat(16)11
Avg Revenue beat(16)2.25%
PT rev (1m)0%
PT rev (3m)-3.11%
EPS NQ rev (1m)-158.82%
EPS NQ rev (3m)-250.15%
EPS NY rev (1m)0%
EPS NY rev (3m)16.35%
Revenue NQ rev (1m)-3.61%
Revenue NQ rev (3m)-3.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 30.3
P/S 3.19
P/FCF 33.33
P/OCF 32.52
P/B 68
P/tB N/A
EV/EBITDA 27.53
EPS(TTM)-0.01
EYN/A
EPS(NY)0.19
Fwd EY3.3%
FCF(TTM)0.17
FCFY3%
OCF(TTM)0.17
OCFY3.08%
SpS1.76
BVpS0.08
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.14%
ROE 4.05%
ROCE 9.09%
ROIC 7.18%
ROICexc 12.07%
ROICexgc 37.84%
OM 8.53%
PM (TTM) 0.19%
GM 85.41%
FCFM 9.57%
ROA(3y)-12.04%
ROA(5y)-20.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.42%
GM growth 5Y9.44%
F-Score8
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 16.1
Debt/FCF 7.89
Debt/EBITDA 5.95
Cap/Depr 5.73%
Cap/Sales 0.24%
Interest Coverage 0.92
Cash Conversion 77.26%
Profit Quality 5041.52%
Current Ratio 2.19
Quick Ratio 1.57
Altman-Z 0.41
F-Score8
WACC10.19%
ROIC/WACC0.7
Cap/Depr(3y)10.42%
Cap/Depr(5y)18.7%
Cap/Sales(3y)0.68%
Cap/Sales(5y)0.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y1951.3%
EPS Next 2Y518.97%
EPS Next 3Y289.56%
EPS Next 5Y158.41%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y38.35%
Revenue growth 5Y70.26%
Sales Q2Q%42.78%
Revenue Next Year27.72%
Revenue Next 2Y22.93%
Revenue Next 3Y19.87%
Revenue Next 5Y19.2%
EBIT growth 1Y173.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year227.83%
EBIT Next 3Y97.87%
EBIT Next 5Y62.93%
FCF growth 1Y173.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.41%
OCF growth 3YN/A
OCF growth 5YN/A

XERIS BIOPHARMA HOLDINGS INC / XERS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for XERIS BIOPHARMA HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to XERS.


Can you provide the valuation status for XERIS BIOPHARMA HOLDINGS INC?

ChartMill assigns a valuation rating of 5 / 10 to XERIS BIOPHARMA HOLDINGS INC (XERS). This can be considered as Fairly Valued.


How profitable is XERIS BIOPHARMA HOLDINGS INC (XERS) stock?

XERIS BIOPHARMA HOLDINGS INC (XERS) has a profitability rating of 5 / 10.


How financially healthy is XERIS BIOPHARMA HOLDINGS INC?

The financial health rating of XERIS BIOPHARMA HOLDINGS INC (XERS) is 4 / 10.